Eugene R. Schiff
- Hepatology top 0.01%
- Epidemiology top 0.01%
- Infectious Diseases top 0.2%
- Surgery top 1%
- Rheumatology top 0.5%
- Co-authors
- Jules L. DienstagK. Rajender ReddyLennox J. JeffersZachary GoodmanJanice K. AlbrechtMitchell L. ShiffmanStuart C. GordonLeon Schiff
- Topics
- Hepatitis C virus research (181 papers)Liver Disease Diagnosis and Treatment (176 papers)Hepatitis B Virus Studies (138 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Eugene R. Schiff
362 papers receiving 27.7k citations
Hit Papers
Peers
Comparison fields: 5 of 161
- Hepatology 22.8k
- Epidemiology 22.5k
- Infectious Diseases 3.2k
- Surgery 2.7k
- Rheumatology 1.3k
Countries citing papers authored by Eugene R. Schiff
This map shows the geographic impact of Eugene R. Schiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene R. Schiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene R. Schiff more than expected).
Fields of papers citing papers by Eugene R. Schiff
This network shows the impact of papers produced by Eugene R. Schiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene R. Schiff. The network helps show where Eugene R. Schiff may publish in the future.
Co-authorship network of co-authors of Eugene R. Schiff
This figure shows the co-authorship network connecting the top 25 collaborators of Eugene R. Schiff. A scholar is included among the top collaborators of Eugene R. Schiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugene R. Schiff. Eugene R. Schiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease | 0 |
| 2 | 24 | |
| 3 | 0 | |
| 4 | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study | 5 |
| 5 | Diagnosing and treating hepatitis C virus infection. | 11 |
| 6 | The current economic burden of cirrhosis. | 124 |
| 7 | 89 | |
| 8 | 87 | |
| 9 | 142 | |
| 10 | 87 | |
| 11 | 15 | |
| 12 | 116 | |
| 13 | 6 | |
| 14 | Methionine, choline and betaine in oral solution for the treatment of alcoholic fatty liver: results of a multicenter randomized double-blind clinical trial | 1 |
| 15 | A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy | 30 |
| 16 | 10 | |
| 17 | 90 | |
| 18 | 10 | |
| 19 | HIV-1 and HTLV-I infection in renal transplant recipients. | 4 |
| 20 | 1 |
About Eugene R. Schiff
Eugene R. Schiff is a scholar working on Hepatology, Epidemiology and Transplantation, having authored 372 papers that have together received 28.9k indexed citations. Recurring topics across this work include Hepatitis C virus research (181 papers), Liver Disease Diagnosis and Treatment (176 papers) and Hepatitis B Virus Studies (138 papers). The work is most often cited by research in Hepatology (22.8k citations), Epidemiology (22.5k citations) and Infectious Diseases (3.2k citations). Eugene R. Schiff has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Jules L. Dienstag, K. Rajender Reddy, Lennox J. Jeffers, Zachary Goodman, Janice K. Albrecht, Mitchell L. Shiffman, Stuart C. Gordon, Leon Schiff, John G. McHutchison and William M. Lee. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.